SVRA Stock Cash Flow Statements

Savara Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Savara Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2009-06-12

cash flows from operating activities:
net income	-30,401,000	-26,639,000	-29,044,000	-24,248,000	-22,243,000	-20,346,000	-16,099,000	-16,599,000	-11,443,000	-10,557,000	-10,300,000	-10,386,000	-9,164,000	-8,300,000	-11,310,000	-10,546,000	-10,941,000	-10,217,000	-13,741,000	-11,063,000	-9,390,000	-15,421,000	-31,719,000	-12,403,000	-21,939,000	-12,112,000	-10,514,000	-12,560,000	-11,593,000	-26,849,000	-6,504,000	-6,816,000	-10,608,000	-5,869,000	-6,035,000	-8,152,000	-10,706,000	-11,207,000	-10,163,000	-9,912,000	-10,151,000	-9,616,000	-7,313,033	-7,866,497	-7,151,889	-6,370,581	-5,704,715	-5,253,531	-4,941,172	-5,580,867	-3,996,756	-3,199,053	-4,211,163	-4,152,517	-3,157,010
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	33,000	30,000	32,000	33,000	33,000	32,000	32,000	29,000	8,000	8,000	7,000	8,000	8,000	8,000	2,000	40,000	47,000	47,000	66,000															11,000	13,000	25,000	29,000	32,000	41,000	38,000	37,000	30,000	25,237	25,775	22,538	11,450	10,779	10,064	8,879	9,795	12,478	10,638	36,739	30,192	32,246
reduction in the carrying value of right-of-use assets	40,000	38,000
foreign currency loss														13,000										-116,000	-110,000	59,000
amortization of debt issuance costs	129,000	70,000	68,000	68,000	67,000	68,000	68,000	68,000	67,000	68,000	68,000	68,000	45,000	153,000	139,000	136,000	137,000	140,000	126,000	122,000	125,000	134,000	150,000	140,000	145,000	147,000	136,000	109,000	114,000	109,000	100,000	97,000
loss on extinguishment of debt	0	546,000																													0	0
accretion on discount to short-term investments	-801,000	-1,149,000																161,000	145,000	23,000	-44,000	-69,000	-157,000	-316,000	-346,000	-342,000					-102,000
stock-based compensation	2,669,000	2,972,000	3,036,000	2,371,000	2,196,000	2,257,000	1,361,000	995,000	958,000	864,000	561,000	450,000	456,000	574,000	853,000	690,000	771,000	946,000	807,000	1,931,000	1,175,000	1,194,000	1,149,000	1,145,000	1,147,000	1,000,000	945,000	1,988,000	392,000	412,000	202,000	114,000
changes in operating assets and liabilities:
prepaid expenses and other current assets	880,000	859,000	974,000	-680,000	-2,920,000	243,000	-1,598,000	765,000	116,000	261,000	79,000	-80,000	-301,000	1,638,000	-271,000	-598,000	-1,049,000	879,000	-623,000	1,072,000	-388,000	-195,000	-246,000	279,000	46,000	69,000	-69,000	13,000	29,000	927,000	-838,000	-455,000
non-current assets	0	-768,000	825,000	0	0	-814,000	780,000	0	-36,000	-756,000	771,000	-25,000	-471,000	-332,000		6,000	-27,000	-863,000		-23,000	9,000	-821,000	803,000	166,000	115,000	-953,000
accounts payable and accrued expenses and other current liabilities	1,190,000	-3,148,000	2,260,000	1,375,000	1,336,000	-770,000	1,470,000	3,059,000	988,000	-976,000	445,000	1,699,000	16,000	-2,479,000	-278,000	928,000	-1,632,000	-781,000	70,000	1,166,000	804,000	-3,180,000	139,000	-712,000	188,000	953,000
net cash from operating activities	-26,261,000	-27,189,000	-23,281,000	-22,668,000	-22,495,000	-20,644,000	-15,603,000	-13,160,000	-10,272,000	-12,026,000	-8,651,000	-8,162,000	-9,316,000	-8,425,000	-9,363,000	-8,927,000	-12,194,000	-9,597,000	-12,300,000	-6,705,000	-7,752,000	-13,079,000	-9,946,000	-11,413,000	-12,905,000	-10,859,000	-10,493,000	-8,762,000	-10,349,000	-9,671,000	-9,470,000	-8,249,000	-7,336,000	-3,179,000	-7,329,000	-10,969,000	-7,641,000	-11,328,000	-8,811,000	-8,256,000	-8,533,000	-7,349,000	-6,014,624	-5,368,081	-6,989,992	-6,272,303	-4,860,287	-3,769,045	-4,671,266	-4,488,364	-3,349,540	-3,216,073	-2,941,690	-4,411,565	-4,543,258
capex	-15,000	-3,000	9,000	-3,000	-21,000	-10,000	-24,000	-43,000	-225,000	-4,000	0	-4,000	0	0	-40,000	-11,000	0	0	-5,000	-18,000	-20,000	-4,000	-10,000	-6,000	-36,000	-96,000	-60,000	-16,000	-46,000	-19,000	-434,000	-1,000	0	0	0	-1,000	-2,000	-5,000	-47,000	-27,000	-21,000	-70,000	-10,432	-27,007	-102,941	-6,620	-1,433	-28,172	-12,451	-4,725	-55,266	-4,993	-18,553	-187,363	0
free cash flows	-26,276,000	-27,192,000	-23,272,000	-22,671,000	-22,516,000	-20,654,000	-15,627,000	-13,203,000	-10,497,000	-12,030,000	-8,651,000	-8,166,000	-9,316,000	-8,425,000	-9,403,000	-8,938,000	-12,194,000	-9,597,000	-12,305,000	-6,723,000	-7,772,000	-13,083,000	-9,956,000	-11,419,000	-12,941,000	-10,955,000	-10,553,000	-8,778,000	-10,395,000	-9,690,000	-9,904,000	-8,250,000	-7,336,000	-3,179,000	-7,329,000	-10,970,000	-7,643,000	-11,333,000	-8,858,000	-8,283,000	-8,554,000	-7,419,000	-6,025,056	-5,395,088	-7,092,933	-6,278,923	-4,861,720	-3,797,217	-4,683,717	-4,493,089	-3,404,806	-3,221,066	-2,960,243	-4,598,928	-4,543,258
cash flows from investing activities:
purchase of property and equipment	-15,000	-3,000	9,000	-3,000	-21,000	-10,000	-24,000	-43,000	-225,000	-4,000	0	-4,000			-40,000	-11,000			-5,000	-18,000	-20,000	-4,000	-10,000	-6,000	-36,000	-96,000	-60,000	-16,000	-46,000	-19,000	-434,000	-1,000
purchase of available-for-sale securities	-39,658,000	-15,068,000	-32,064,000	-138,714,000	-3,441,000	-30,697,000	-38,805,000	-94,543,000	-30,781,000	-30,091,000	-73,411,000	0	0	-16,004,000	-22,528,000	-24,096,000	-20,126,000	-94,319,000	-15,926,000	-34,543,000	0	-35,614,000	-18,741,000	-12,006,000	-46,163,000	-46,035,000	-34,390,000	-63,380,000	-8,833,000	-15,891,000	-43,419,000
maturity of available-for-sale securities	64,000,000	44,400,000	49,950,000	40,550,000	33,000,000	41,500,000	45,400,000	38,000,000	30,000,000	24,000,000	14,200,000	33,000,000	25,200,000	58,393,000
net cash from investing activities	24,327,000	29,329,000	17,895,000	-98,167,000	29,538,000	10,793,000	6,571,000	-56,586,000	-1,006,000	-6,095,000	-59,211,000	32,996,000	25,195,000	53,665,000	-1,268,000	12,983,000	-3,432,000	-77,739,000	-381,000	-6,861,000	18,080,000	-1,785,000				7,320,000	869,000				-39,053,000	-33,444,000	553,000	2,829,000	3,686,000									2,812,393			426,562				-253,266	-702,993	-2,149,553	-4,059,363
cash flows from financing activities:
repayment of long-term debt	0	-27,230,000									0	0																			0	0
proceeds from long-term debt	0	29,598,000									0	0
proceeds from exercise of stock options	65,000	165,000	48,000	237,000	11,000	51,000	89,000	63,000	104,000	27,000					1,000	10,000	3,000	2,000	0	0	38,000	48,000	-1,000	44,000	61,000	6,000	8,000	17,000	30,000	3,000
reimbursement of commissions from the prior issuance of common stock upon at the market sales			0	0
repurchase of shares for minimum tax withholdings	-114,000	-215,000	-897,000	-94,000	-2,000	-2,000	-1,025,000	-182,000	0	-1,000	-1,000	-1,000	0	-1,000
net cash from financing activities	-49,000	2,318,000	-843,000	118,316,000	55,000	49,000	7,895,000	74,755,000	104,000	26,000	1,000	-1,000	88,000	-1,000	6,000	10,000	324,000	120,466,000	0	1,827,000	2,328,000	-466,000	25,248,000	5,708,000	19,056,000	4,896,000	9,096,000	45,810,000	16,000	271,000	50,756,000	435,000			-8,336,000	2,851,000			-48,000	14,818,000			20,242,403	2,168,841	3,902,233	7,977,523	-116,337	-242,612					-3,170	-47,742
effect of exchange rate changes on cash and cash equivalents	-137,000	-30,000	-70,000	82,000	-19,000	2,000	32,000	-64,000	-65,000	-21,000	120,000	-145,000	-41,000	-24,000	-62,000	-20,000	-27,000	-28,000	342,000	-159,000	-54,000	41,000	-34,000	70,000	-71,000	13,000	-117,000	6,000	-19,000	11,000	75,000	-62,000
increase in cash and cash equivalents	-2,120,000	4,428,000					-1,105,000	4,945,000	-11,239,000	-18,116,000	-67,741,000	24,688,000	15,926,000	45,215,000	-10,687,000	4,046,000	-15,329,000	33,102,000				-15,289,000	32,019,000	955,000	-8,841,000	1,370,000	-645,000
cash and cash equivalents beginning of period	0	15,128,000	0	0	0	26,585,000	0	0	0	52,100,000	0	0	0	34,012,000	0	0	0	22,880,000	0	0	0	49,804,000	0	0	0	24,301,000	0	0	0	22,121,000	0	0
cash and cash equivalents end of period	-2,120,000	19,556,000	-6,299,000	-2,437,000	7,079,000	16,785,000	-1,105,000	4,945,000	-11,239,000	33,984,000	-67,741,000	24,688,000	15,926,000	79,227,000	-10,687,000	4,046,000	-15,329,000	55,982,000	-12,339,000	-11,898,000	12,602,000	34,515,000	32,019,000	955,000	-8,841,000	25,671,000	-645,000	1,342,000	1,482,000	22,122,000	2,308,000	-41,320,000
supplemental disclosure of cash flow information:
cash paid for interest	499,000	1,325,000	505,000	541,000	542,000	536,000	536,000	531,000	509,000	464,000	428,000	329,000	373,000	484,000									503,000	538,000	530,000	528,000	368,000	353,000	351,000	334,000
issuance of common stock and pre-funded warrants in underwritten offering, net of offering costs
issuance of common stock issued in underwritten offering, net of offering costs
issuance of common stock upon exercise of prefunded warrants
issuance of common stock upon at the market offerings			0																0	0			1,000	5,664,000	19,037,000	4,890,000	12,000	0	0	493,000	675,000	891,000
decrease in cash and cash equivalents			-6,299,000	-2,437,000	7,079,000	-9,800,000														-11,898,000
amortization of right-of-use assets				36,000	36,000	35,000	34,000	33,000	16,000	15,000	35,000	35,000	33,000	33,000	135,000	-20,000	59,000	57,000	53,000
accretion on premium to short-term investments				-1,477,000	-1,125,000	-1,370,000
issuance of common stock and pre-funded warrants in underwritten public offering, net of offering costs
issuance of common stock in underwritten public offering, net of offering costs
foreign currency gain					125,000	21,000	-12,000	-2,000							77,000	7,000	-42,000	57,000
(accretion on discount)/amortization on premium to short-term investments
sale of available-for-sale securities											0	0	0	11,276,000	5,700,000					0	3,000,000	5,780,000		2,000	3,478,000	10,651,000
issuance of common stock and pre-funded warrants in registered direct offering, net of offering costs							0
amortization on premium to short-term investments								-1,508,000	-913,000	-924,000	-357,000	61,000	104,000	267,000
foreign currency (gain) loss										-29,000		8,000										-156,000
non-cash interest income
long-term liabilities															74,000	-71,000	-24,000	-23,000	-20,000	56,000	-162,000	-305,000		-76,000	90,000	-193,000
repurchase of outstanding pre-funded warrants															0	0	0	-3,909,000
issuance of common stock and pre-funded warrants in public offering, net of offering costs															83,000	0	321,000	121,827,000
issuance of common stock upon exercise of warrants															0	0	0	2,546,000	0								0	0	1,000	18,000	0	-1,000
acquired in-process research and development																			0	0	0	5,367,000
change in fair value of financial instruments
purchase of in-process research and development
non-cash transactions:
common stock issued for acquired in-process research and development
changes in fair value of financial instruments																				-60,000	-54,000	-2,000		136,000	41,000	77,000		-10,000	-34,000	96,000	0	43,000
noncash interest expense
amortization (accretion) on premium or discount to short-term investments																501,000
maturities of available-for-sale securities																34,590,000	16,700,000	16,580,000	15,550,000	27,700,000	15,100,000	31,300,000	35,500,000	18,600,000	27,800,000	42,800,000	34,400,000	24,846,000	14,200,000	25,300,000
non-cash transactions
cash paid for interest, including end of period charge due upon long-term debt amendment
repayment of debt facility																			0	0	0	-514,000
cash paid for interest, including end of period charge due upon debt facility amendment																	490,000	484,000
impairment of goodwill																							19,432,000	0
change in fair value of contingent consideration																							0	0	131,000	133,000	135,000	134,000	131,000	-134,000	132,000	131,000
noncash interest income																					10,000	133,000
gain on short-term investments
sales of available-for-sale securities
issuance of securities in private financing
capital lease obligation principal payments																							1,000	0			-289,000	1,000	-15,000	-243,000	0	-455,000
settlement of contingent consideration																							0	0
purchase in-process research and development																				0	0	-3,247,000
acquisition of in-process research and development																				0	0	-2,120,000
cash paid for interest including end of period charge due upon debt facility amendment																				495,000
depreciation and amortization including right-of-use assets																					213,000	242,000	238,000	233,000	232,000	307,000
cash paid for interest and end of period charge due upon debt facility amendment																						990,000
impairment of acquired ipr&d																											0	0	0	21,692,000
non-cash interest (income) / expense
write-off of ipr&d upon acquisition
benefit for deferred taxes																											-2,502,000	0	0	-4,555,000
proceeds from debt facility																															0	0
issuance of common stock upon public offering																											0				50,076,000	0
common stock issued for ipr&d																											0	0
noncash interest (income) / expense																								111,000	-65,000	-4,000
acquired ipr&d																												0
net cash used by investing activities
issuance of common stock upon public offerings
noncash transaction:
net cash provided (used) by investing activities
depreciation																											139,000	127,000	153,000	107,000	91,000	91,000
non-cash interest
write-off of acquired ipr&d
accretion on discount to short-term investments and convertible promissory notes																											-354,000	-268,000	-140,000	-138,000
issuance of call option derivative																															0
grant and award receivable																															0	0
cash acquired through merger																															0	0
proceeds from convertible promissory notes
extinguishment and derecognition of put options																															0	0
conversion of convertible notes into common stock																															0	0
shares issued in connection of business combination and assumed equity awards																															0	0
accretion of redeemable convertible preferred stock
beneficial conversion feature																															0	0
noncash interest																												29,000	19,000	35,000	-59,000	-5,000
foreign currency gain/																												7,000	-155,000	61,000		71,000
tax refund receivable																												-156,000	-364,000	-873,000	331,000	-119,000
deferred rent																												-10,000	-6,000	-7,000	-12,000	-7,000
accounts payable and accrued expenses																												1,835,000	110,000	-554,000	16,000	-1,704,000
net cash from / (used in) investing activities																													11,834,000	9,390,000
cash flows from financing activity:
increase / (decrease) in cash and cash equivalents																													1,482,000	1,000	2,308,000	-41,320,000
accretion on discount to convertible promissory notes
proceeds from convertible promissory note																															0	0
proceeds from issuance of series c preferred stock
net assets acquired in business combination of serendex
equipment under capital lease
contingent liability related to purchase of serendex
conversion of convertible notes into preferred stock
accretion of series a redeemable convertible preferred stock																															0	0
accretion of series b redeemable convertible preferred stock																															0	0
accretion of series c redeemable convertible preferred stock																															0	0
cash paid for income taxes
proceeds from exercise of stock option
issuance of common stock for serendex
share-based compensation expense related to employee stock options																																		461,000	692,000	645,000	647,000	659,000
amortization of debt issuance costs and debt discount																																		104,000	62,000	615,000	163,000	169,000	156,000
changes in assets and liabilities:
decrease in prepaid expenses and other assets																																		515,000				153,000				438,000										-204,810
decrease in accounts payable																																		-127,000
increase/(decrease) in accrued liabilities																																		1,726,000
proceeds from maturities of certificates of deposit																																		498,000	3,686,000	4,150,000	2,988,000	4,383,000	4,980,000	4,707,000	2,490,000	4,847,000	2,581,000	7,452,000	947,000	5,679,000	2,988,000	4,722,000	3,145,000	6,393,000
proceeds from sales of certificates of deposit																																		2,241,000
security deposit for sublease																																		90,000
purchases of property and equipment																																			0	-1,000	-2,000	-5,000	-47,000	-27,000	-21,000	-70,000	-10,432	-27,007	-102,941	-6,620	-1,433	-28,172	-12,451	-4,725	-55,266	-4,993	-18,553	-187,363
payments made on debt facility																																		-368,000	-10,359,000
costs paid in connection with debt facility																																		-50,000	0	-76,000	-9,000	-38,000
proceeds from sale of common stock																																			2,016,000	3,909,000	5,973,000	8,060,000	0	0	2,131,000	9,000	15,435,454	2,291,068	4,181,080	8,293,398	0	0
payments for offering costs																																			-56,000	-94,000	-338,000	-601,000	-13,000	-20,000	-96,000	-13,000
payments for capital lease																																		-3,000	-2,000	-2,000	-2,000	-2,000	-2,000	-2,000	-1,000	-2,000
net cash (used in)/provided by financing activities																																		-421,000								-6,000
net (decrease)/increase in cash and cash equivalents																																		-771,000					-9,155,000	10,993,000	-6,720,000	-7,874,000								-1,090,517		-3,868,154	-5,094,413	-8,518,670
cash and cash equivalents at beginning of period																																		8,542,000	0	0	0	23,052,000	0	0	0	35,808,000	-92	0	0	25,681,092	0	0	0	22,500,440	0	0	0	43,569,947	9,849,904
cash and cash equivalents at end of period																																		7,771,000	-11,979,000	-3,969,000	969,000	23,521,000	-9,155,000	10,993,000	-6,720,000	27,934,000	9,826,395	-386,847	-3,479,700	29,848,152	-4,550,062	-14,741,082	23,562,313	21,409,923	-3,588,270	-3,868,154	-5,094,413	35,051,277	5,306,646
gain on bargain purchase																																											-56	0	-33,000	-452,944
impairment of ipr&d
benefit for deferred tax liability
write-off of property and equipment
changes in assets and liabilities, net of effect of acquisitions:
increase/(decrease) in prepaid expenses and other assets
(decrease)/increase in accounts payable
(decrease)/increase in accrued liabilities
purchases of certificates of deposit																																							-5,478,000	-249,000	-2,690,000	-5,296,000	-6,971,980	-4,482,000	-1,236,000	-6,745,020	-2,560,005	-15,423,030	-996,000	-2,988,000	-2,241,000	-4,722,000	-3,547,000	-5,312,000
security deposit for new lease
cash obtained through acquisition																																											-480	0
proceeds from borrowings under debt facility
proceeds from sale and exercise of warrants
decrease/(increase) in prepaid expenses and other assets																																				-539,000								-28,081	-113,627	202,314				140,213
(decrease)/increase in accounts payable and accrued liabilities																																						-1,134,000							-138,396	-61,996
proceeds from exercise of warrants																																												0
net decrease in cash and cash equivalents
increase in accounts payable and accrued liabilities																																											872,902				972,973	1,009,943			-7,016	80,874	580,102	-533,492	-1,534,852
net cash provided by/(used in) investing activities																																					2,986,000	4,378,000								2,461,840			2,136,549	3,400,275
net increase/(decrease) in cash and cash equivalents																																					969,000	469,000								4,167,060		-14,741,082
net cash provided by/(used in) financing activities																																						7,419,000
write-off of fixed assets																																																				0
increase in accounts payable
increase in accrued liabilities
share-based compensation expense																																								544,000	512,000	1,066,000
(increase)/decrease in prepaid expenses and other assets																																								-127,000
security deposit for new sublease
net cash (used in)/provided by investing activities																																								4,431,000	-221,000	-519,000
proceeds from borrowings under term loan
costs paid in connection with term loan
increase/(decrease) in accounts payable and accrued liabilities																																									1,631,000	733,000								563,439
loss on change in fair value of contingent consideration
increase in prepaid expenses and other assets																																																						-34,078	-57,879
effect of exchange rate changes on cash																																															0	-223	1,129	-2,428
net increase in cash and cash equivalents																																											9,826,487	-386,847											-4,543,258
share-based compensation expense related to employee stock options and restricted stock issued																																												689,232	424,382	399,454	440,801	442,328	365,137	351,556	385,458	359,543	336,824	377,505
payments for financing and offering costs																																												-122,227	-278,912	-315,875	-116,337	-242,612					-3,170	-47,742
loss on disposals of equipment
loss on fair value of warrants
loss/(gain) on change in fair value of contingent consideration																																															0	0	7,500	27,500
amortization of debt discount
forgiveness of employee receivable
impairment loss – write-off of goodwill
expenses related to options issued to non-employees
expenses paid by issuance of common stock
expenses paid by issuance of warrants
expenses paid by issuance of preferred stock
expenses related to stock warrants issued
equity in loss of investee
in-process research and development
write-off of license agreement
impairment of equipment
cumulative effect of change in accounting principle
amortization of premium / (accretion of discount) on investments in securities																																																			0	2,957	8,173	10,710
proceeds from sale of certificate of deposit
purchases of other investment securities
proceeds from maturities and sales of other investment securities
proceeds from sale of property and equipment
cash obtained through acquisitions, net of cash paid																																														3,534,480
payment on obligation under license agreement
issuance of note receivable – related party
payments on note receivable
advance to investee
cash transferred in rescission of acquisition
cash received in rescission of acquisition
proceeds from sale or exercise of warrants
proceeds from sale of preferred stock
repurchase of subject to vesting shares
repurchase of warrants
payments on notes payable and long-term debt
proceeds from issuance of notes payable and detachable warrants
cash paid in lieu of fractional shares for reverse stock split
impairment loss — write-off of goodwill
amortization of premium/(accretion of discount) on investments in securities
increase in prepaid and other current assets
cash paid for acquisitions, net of cash acquired
issuance of note receivable — related party
issuance of note receivable - related party
purchases of other short-term investments
proceeds from maturities and sales of other short-term investments
gain on disposals of equipment
gain on change in fair value of contingent consideration																																																			105,109			-114,388
increase in prepaid and other assets
(gain) loss on disposals of fixed assets																																																				0	0	4,503
expense related to options issued to non-employees
proceeds from maturities and sales of certificates of deposit
(gain) loss on change in fair value of contingent consideration
maturity of certificates of deposit																																																					1,416,000	1,440,000
proceeds from sales and maturities of other short-term investments
write-off of assets available-for-sale
(gain) loss on disposal of fixed assets
write-off assets available-for-sale
proceeds from sales and maturities of short-term investments
purchases of short-term investments
expenses related to share-based compensation
expense related to stock options issued to non-employees
accretion of discount on investments in securities
purchase of certificate of deposit
maturity of certificate of deposit
cash acquired from acquisitions, net of cash paid
proceeds of restricted cash for preferred stock dividends
payment to escrow for preferred stock dividends obligation
loss on disposals of fixed assets
expenses related to employee stock options and restricted stock issued
net increase in cash
cash at beginning of period
cash at end of period
1.
gain on disposal of fixed assets																																																							279
fair value of warrant liability
expenses related to employee stock options																																																							173,958
expenses paid by warrants
expenses paid by preferred stock
accretion of discount
gain /loss on disposals of property and equipment
decrease in other long-term liabilities
payment of financing and offering costs
payments of notes payable and long-term debt
share-based compensation for employee awards
increase in other long-term liabilities
share-based compensation for employee equity awards
share-based compensation for non-employee options
expenses paid by issuance of common stock to non-employees
write-off of assets available for sale
payments of financing and offering costs
loss on fair value of warrant liability
expenses related to employee stock options issued
write-off assets available for sale
increase in long-term liabilities
impairment loss — write off of goodwill
increase in sponsored research payable and license obligation
cash acquired in acquisition of subsidiary

We provide you with 20 years of cash flow statements for Savara stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Savara stock. Explore the full financial landscape of Savara stock with our expertly curated income statements.

The information provided in this report about Savara stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.